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Abstract: We aim to estimate the diagnostic performances of anterior gradient homolog-2 
(AGR2) and Leucine-rich repeat-containing-G-protein-coupled receptor 5 (LGR5) in 
peripheral blood (PB) as mRNA biomarkers in colorectal cancer (CRC) and to explore 
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their prognostic significance. Real-time PCR was used to analyze AGR2 and LGR5 in 54 
stages I-IV CRC patients and 19 controls. Both mRNAs were significantly increased in PB 
from CRC patients compared to controls. The area under the receiver-operating 
characteristic curves were 0.722 (p = 0.006), 0.376 (p = 0.123) and 0.767 (p = 0.001) for 
AGR2, LGR5 and combined AGR2/LGR5, respectively. The AGR2/LGR5 assay resulted in 
67.4% sensitivity and 94.7% specificity. AGR2 correlated with pT3–pT4 and high-grade 
tumors. LGR5 correlated with metastasis, R2 resections and high-grade. The progression-free 
survival (PFS) of patients with high AGR2 was reduced (p = 0.037; HR, 2.32), also in the 
stage I-III subgroup (p = 0.046). LGR5 indicated a poor prognosis regarding both PFS  
(p = 0.007; HR, 1.013) and overall survival (p = 0.045; HR, 1.01). High AGR2/LGR5 was 
associated with poor PFS (p = 0.014; HR, 2.8) by multivariate analysis. Our findings 
indicate that the assessment of AGR2 and LGR5 in PB might reflect the presence of 
circulating tumor cells (CTC) and stem cell like CTC in CRC. Increased AGR2 and LGR5 
are associated with poor outcomes. 
Keywords: colorectal cancer; real-time PCR; circulating tumor cells; prognostic markers; 
stem cells; anterior gradient homolog-2; leucine-rich repeat-containing G-protein-coupled 
receptor 5 
 
1. Introduction 
Colorectal cancer (CRC) is one of the leading causes of cancer-associated morbidity and mortality 
across the world. The predicted number of deaths in 2011 in the European Union due to CRC was 
162,026 [1]. The stage at diagnosis and the possibilities for curative surgery remain the most important 
prognostic factors.  
The development of blood-borne metastasis is ultimately responsible for most CRC-related deaths. 
Sensitive methods to detect circulating tumor cells (CTC) could serve as prognostic or predictive tools 
to identify patients at a high risk of disease progression who could be selected for additional treatment [2].  
CTC are identified mainly by using antibodies against epithelial antigens or molecular approaches. 
The PCR amplification of tissue- or tumor-specific mRNA is commonly used to detect circulating or 
occult metastatic cells. Systematic reviews, meta-analyses and prospective studies [3–7] provide 
coherent evidence that the molecular detection of CTC in the peripheral blood (PB) is of strong 
prognostic significance in patients with CRC.  
Our study aimed to evaluate promising CRC-specific mRNAs for multi marker detection of CTC in 
PB. We previously [8,9] identified anterior gradient homolog-2 (AGR2) and plakophilin-3 as potential 
CTC markers in gastrointestinal cancer through an in silico profile of gene expression and quantitative 
real-time reverse-transcription PCR (qRT-PCR). Moreover, AGR2 has been included in the molecular 
signature that defined CTC in metastatic breast, prostate and colorectal cancers [10,11].  
AGR2 encodes a 17 kDa secreted protein, homologue of the Xenopus cement gland gene  
XAG-2 [12]. Although its functions in humans are poorly understood, recent reports indicate that 
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AGR2 can induce cellular transformation and tumor growth, promote cell survival through inhibition 
of p53, enhance tumor cell adhesion to the substratum and enhance cell migration [13–15]. 
Recent data [2,10,11,16,17] suggest that CTC encompass a heterogeneous cell population with 
different tumorigenic capabilities and include cells characterized by an epithelial-mesenchymal 
plasticity (EMP) with transient loss of epithelial markers. In that sense, the use of different mRNA 
biomarkers will yield better results in the identification of CTC and rare cell subsets of biological 
relevance. Thus, it has been hypothesized that only CTC with tumor-initiating properties will 
eventually complete the metastatic cascade and will develop clinically relevant metastases [18]. 
The leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) also known as  
G-protein-coupled receptor 49 (GPR49), has been recently reported as a marker for stem cells (SC) in 
the small intestine and colon [19]. Recently [20,21] it was shown that the LGR5 gene and protein were 
markedly over expressed in the majority of advanced CRCs and in CRC cell lines derived from 
metastatic tumors. Moreover, high LGR5 expression has been associated with poor progression-free 
survival for CRC patients [22]. 
Thus, we hypothesized that LGR5 mRNA expression in PB of CRC patients could indicate the 
presence of circulating tumor cells with stem cell properties.  
The primary aims of our study were to estimate prospectively the diagnostic accuracy and 
usefulness of AGR2 mRNA in PB as a surrogate biomarker of CTC and to explore its prognostic 
significance. Additionally, the blood expression of the intestinal stem-cell (ISC) marker LGR5 was 
evaluated for correlations with AGR2 and clinical parameters. Our findings revealed that molecular 
assessment of AGR2 and LGR5 can serve as a marker of CTC and ISC-like CTC in CRC patients, 
which underscores their potential clinical relevance as predictors of disease outcome. 
2. Results and Discussion 
2.1. Results 
2.1.1. Patients and Clinical Data 
Starting in July 2004, 54 patients with histological proven CRC and 19 controls were consecutively 
recruited for this study. This sample size allowed us to estimate an expected area under the ROC curve 
of 0.70 with a standard error of 0.065. Ninety per cent of the subjects were included within the first 
two years. The clinical characteristics of the patients are shown in Table 1. 
Table 1. Patient baseline and clinical characteristics. 
 Mean (SD) Range 
Age (years) 62.7 (9.6) 31–80 
 N % 
<60 years 20 37.0 
≥60 years 34 63.0 
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Table 1. Cont. 
Gender   
Female 21 38.9 
Male 33 61.1 
Stage   
I-II 6 11.1 
III 12 22.2 
IV 36 66.7 
pT   
pT1-pT2 6 14.1 
pT3 36 66.7 
pT4 8 14.8 
pTx 4 7.4 
pN   
pN0 13 24.1 
pN1 26 48.1 
pN2 11 20.4 
pNx 4 7.4 
M   
M0 18 33.3 
M1 36 66.7 
Residual disease status   
R0-R1 16 29.6 
R2 38 70.4 
Number of Metastatic Sites   
0 18 33.3 
1 25 46.3 
≥2 11 20.4 
Location of Metastasis   
None 18 33.3 
Liver Only 23 42.6 
Liver and Other 11 20.4 
Non-liver Metastasis 2 3.7 
Grade   
Low Grade 10 18.5 
High Grade 44 81.5 
Vascular/Perineural Invasion   
Unknown 6 11.1 
No 24 44.4 
Yes 24 44.4 
The mean age was 62.2 years (SEM 1.84; median, 62 years; range, 43 to 74 years) in the control 
group and 62.7 (SEM 1.30; median, 62.5; range, 31 to 80 years) in the patient group (t test, p = 0.847). 
The ratio of males to females was similar in the controls (men 63.2%) and the patients (men 61%)  
(χ2 test, p = 0.875). 
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PB samples were obtained after R0 or R1 surgery in 16 patients. In 38 patients, blood samples were 
obtained before neo-adjuvant chemotherapy or in the presence of active metastatic disease, both of 
which were categorized as R2. In patients with node-negative disease and R0 resection, the mean 
number of lymph nodes analyzed was 12.8 (SEM 2.7; range 7–21). 
Patients with metastatic CRC (n = 38) were grouped into high- (19.4%), intermediate- (36.1%) and 
low-risk groups (44.4%) using performance status, number of tumor sites, alkaline phosphatase and 
white blood cell count, as suggested by Köhne et al. [23] Median overall survival (OS) and 
progression-free survival (PFS) were 98 and 39 weeks, 56 and 26 weeks, and 59 and 14 weeks for the 
low-, intermediate- and high-risk groups, respectively. The median OS tended to be higher  
(log-rank p = 0.061) in the low-risk group (98 weeks; 95% CI, 43.1 to 152.9) compared to the 
combined intermediate/high-risk group (56 weeks; 95% CI, 47.2 to 64.8). 
All patients were followed up until death or the end of the study. Disease progression events 
occurred in 39 patients (72.2%). There were three relapses among stage I–III patients and 36 
progressions of metastatic disease. The median PFS was 44 weeks (95% CI, 24.8 to 63.2 weeks). The 
median OS was 132 weeks (95% CI, 84.4–179.6 weeks), and 34 patients (63%) died of advanced 
disease. The mean (SEM) follow-up time for the patients still alive at the time of the analysis was  
232 (17.8) weeks (median, 232.5 weeks; range, 67 to 335 weeks). 
2.1.2. Expression of AGR2 and LGR5 mRNA Transcripts in Blood Samples 
AGR2 mRNA was quantified in 62 blood samples (84.9%), including 43 samples obtained from 
patients with CRC and 19 from controls. The LGR5 mRNA level was quantified in 67 blood samples 
(90.5%), 48 from CRC patients and 19 from controls. mRNA was insufficient or its quality was inadequate 
for qRT-PCR in 11 (15.1%) and 6 (8.2%) patients‘ samples for AGR2 and LGR5 respectively. 
The mean relative AGR2 mRNA expression was 29.1 (SEM 28.2; median 0.77; range, 0.21 to 536.7) 
in controls and 418.57 (SEM 84.4; median 191.2; range, 0.05 to 1989.5) in cancer patients (t test, p < 0.001). 
Likewise, the AGR2 level was significantly increased (ANOVA, p = 0.007) in patients with stage IV 
CRC (mean 492.6; SEM 114) compared with stage I to III patients (mean 305.4; SEM 122.5) and  
non-cancer controls (mean 29.1; SEM 28.2).  
The mean LGR5 mRNA level was 0.21 (SEM 0.03; median 0.18; range, 0 to 0.4) in controls and 
11.6 (SEM 4.9; median 0.08; range, 0.01 to 146.9) in patients (t test, p = 0.026). The LGR5 level was 
significantly increased (ANOVA, p = 0.038) in patients with stage IV CRC (mean 18.40; SEM 7.70) 
compared with stage I to III patients (mean 0.20; SEM 0.06) and non-cancer controls (mean 0.21; SEM 0.03). 
There was no correlation between AGR2 and LGR5 blood levels in the patients group (Pearson 
correlation coefficient −0.009; p = 0.952). 
ROC curves of circulating mRNAs were constructed in order to be able to discriminate different 
groups (Figure 1). 
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Figure 1. AGR2 and LGR5 ROC curves. mRNA relative levels were quantified in blood 
obtained from patients with colorectal cancer and from controls. Area under the curve 
(AUC), 95% confidence interval and p-values are shown.  
 
Comparing the relative AGR2 levels in patients and controls, the AUC was 0.722 (95% CI,  
0.594–0.849; p = 0.006). According to the ROC curve, a relative level for AGR2 mRNA in the blood of 
1.65 was defined as the optimal cutoff value (Youden index) for differentiating patients with CRC 
from the controls. With this cutoff value for AGR2, the sensitivity and specificity of 62.8% (95% CI, 
46.7 to 76.6) and 94.7% (95% CI, 71.9 to 99.7) respectively, were achieved. At this threshold value, 
AGR2 positivity was associated with CRC diagnostic (p < 0.001).  
The ROC curve for LGR5 showed an AUC of 0.376 (95% CI, 0.233–0.520; p = 0.123). A relative blood 
level of 0.39 was defined as the optimal cutoff point for LGR5. With this cutoff value, the sensitivity 
and specificity for the LGR5 mRNA assay were 18.8% (95% CI, 9.4 to 33.10) and 100% (95% CI,  
79.1 to 99.5) respectively. At this cutoff value, LGR5 positivity tended to associate with CRC 
diagnostic (p = 0.052).  
In CRC patients, relative expression values for AGR2 and/or LGR5 in blood above these cutoff 
points, defined as the Youden index, were found in 16.7% of stage I–II, in 72.7% of stage III and in 
76.9% of stage IV patients (χ2 test; p = 0.016).  
AGR2 and LGR5 markers were analyzed in combination by logistic regression. The predicted 
probabilities of diagnosis generated a ‗combination marker‘ ROC curve. The combination (AGR2/LGR5) 
had an AUC-ROC = 0.767 (95% CI, 0.648–0.886; p = 0.001) which was slightly improved [24] 
compared to AGR2 alone (p = 0.25). The sensitivity and specificity of the combination were 67.4% 
(95% CI, 51.3 to 80.5) and 94.7% (95% CI, 71.9 to 99.7) respectively (Figure 1). 
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2.1.3. Clinic Pathological Characteristics and mRNA Markers in Blood 
The clinical and pathological characteristics and the AGR2 and LGR5 mRNA expression in blood 
from cancer patients are shown in Table 2. 
Table 2. Distribution of clinical and pathological parameters and levels of AGR2 and 
LGR5 mRNA in the blood.  
Parameter AGR2  LGR5  
 Mean SEM p Mean SEM p 
Age (y)   0.459   0.128 
<60 497.0 142.2  22.5 10.0  
≥60 367.3 105.1  5.0 5.0  
Gender   0.075   0.203 
Male 291.1 87.9  5.8 3.9  
Female 633.7 161.5  22.1 11.7  
Stage   0.137 *   0.204 * 
I-II 1.1 0.2  0.3 0.05  
III 471.3 171.2  0.1 0.08  
IV 492.6 113.8  18.4 7.7  
pT   0.002 
a
   0.915 
pT1-T2 82.1 57.5  10.7 10.5  
pT3-T4 453.7 92.4  12.5 5.8  
pN   0.063 *   0.309 * 
Node Negative 306.9 162.3  0.26 0.05  
pN1 311.7 80.4  13.1 7.01  
pN2 795.2 266.3  23.9 16.4  
M   0.283   0.024 
a
 
M0 305.4 122.5  0.18 0.06  
M1 492.6 113.8  18.4 7.7  
R Status   0.671   0.024 
a
 
R0-R1 363.2 156.1  0.13 0.03  
R2 442.6 101.7  40.3 7.01  
Number of Metastatic sites   0.373 *   0.159 * 
0 305.4 122.5  0.18 0.06  
1 407.7 145.0  21.5 10.6  
≥2 628.4 184.7  12.3 9.3  
Grade   0.023 
a
   0.024 
a
 
Low grade 183.0 71.9  0.1 0.04  
High grade 480.9 102.8  14.6 6.1  
Vascular/Perineural Invasion   0.751   0.269 
No 385.8 100.6  6.6 6.5  
Yes 441.2 146.1  18.6 8.5  
AGR2 and LGR5, mean relative expression levels, arbitrary units; SEM: standard error of the median, t-test;  
* ANOVA; 
a
 p values of less than 0.05. 
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A significant higher relative level of AGR2 blood expression was found in pT3-T4 tumors (p = 0.002) 
and high-grade lesions (p = 0.023). There was a tendency (p = 0.063) to higher AGR2 levels associated 
with lymph node metastasis. Increased LGR5 expression was found in patients (Table 2) with stage IV 
(p = 0.024), R2 resections (p = 0.024) or high-grade tumors (p = 0.024). 
Carcinoembryonic antigen (CEA) and carbohydrate antigen 19.9 (CA 19.9) serum levels were 
increased above the upper limits of normal in 46.3% and 38.9% of the patients, respectively. There 
were no correlations between AGR2 or LGR5 mRNA levels with CEA or CA 19.9 in serum  
(Pearson −0.172, −0.155, 0.021 and −0.063 respectively). 
To explore the possible influence of recent surgery on the circulation of tumor cells, we analyzed 
AGR2 and LGR5 levels according to the time interval from operation and blood sampling. The mean 
time from surgery to blood sampling for mRNA quantification was 52.5 weeks (SEM 8.7 weeks; 
median, 18 weeks; range, 1 to 202 weeks). The 25th percentile was 6.75 weeks. There was no 
significant difference in AGR2 and LGR5 levels between time intervals (<6.75 or ≥6.75 weeks) from the 
last surgery.  
In the group of patients with stage IV disease, AGR2 and LGR5 were analyzed according to the 
prognostic subgroups defined as described previously [19]. The mean (SEM) relative AGR2 levels 
were 443.1 (229.6) and 518.8 (129.9) for low- and combined intermediate/high-risk groups, 
respectively (t test, p = 0.759). The median (SEM) relative LGR5 levels were 15.5 (11.7) and 20.6 (10.4) 
for low- and combined intermediate/high-risk groups, respectively (t test, p = 0.746).  
2.1.4. Prognostic Significance of AGR2 and LGR5 in Blood  
To analyze the relationships between biomarker expression and outcomes (PFS and OS) we 
estimated the hazard ratios associated with mRNA levels as continuous variables using Cox regression 
models [25]. There was a trend for a high risk of disease progression associated with increased AGR2 
relative blood expression (HR 1.0; 95% CI, 1.0 to 1.001; p = 0.093). There was no association with the 
risk of death (HR 1.0; 95% CI, 0.999 to 1.001; p = 0.913). However, in stage I to III patients, the risk 
of disease progression was higher with increasing AGR2 level (HR 1.002; 95% CI, 1 to 1.004;  
p = 0.046).  
Increasing relative blood expression of LGR5 mRNA as a continuous variable was associated with a 
higher risk of disease progression (HR 1.013; 95% CI, 1.004 to 1.023; p = 0.007). The risk of death 
was also higher with increasing levels for LGR5 mRNA in the blood (HR 1.01; 95% CI, 1 to 1.020;  
p = 0.045). 
In addition, in order to generate survival curves, we converted continuous mRNAs expression levels 
measured on qRT-PCR to a dichotomous variable, using the mean levels of expression in the patients 
group as a threshold. Kaplan-Meier curves for patients categorized according to AGR2 and LGR5 
mRNA expression in blood are shown (Figures 2–4). 
The median PFS for the group with high AGR2 blood expression were 33 weeks (95% CI, 11 to 55) 
compared with 86 weeks (95% CI, 0 to 305.1) in the group with low AGR2 (log-rank test, p = 0.033). 
Patients with high AGR2 showed worse OS (median 97 weeks; 95% CI, 0 to 262.9) compared with 
those with low AGR2 expression (median 192 weeks; 95% CI, 56.6 to 327.4) although this difference 
was not statistically significant (log-rank test, p = 0.6) (Figure 2). 
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Figure 2. AGR2 and survival analysis. Kaplan-Meier plots of (a) progression-free survival 
(PFS) and (b) overall survival (OS) in colorectal cancer patients according to AGR2 
mRNA expression in blood. Relative quantification of AGR2 mRNA was calculated by the 
2
−Ct
 method using HPRT as a reference gene. Continuous mRNA levels were converted 
to a dichotomous variable using the mean levels of expression as a threshold. p estimates 
by log-rank test. Hazard ratios (HR) were modeled using Cox proportional hazard 
regression analysis. 
 
(a) 
 
(b) 
Analysis of the patients‘ outcome according to LGR5 blood expression revealed that the high LGR5 
group exhibited significantly worse PFS (median 22 weeks; 95% CI, 0 to 48.4) compared with patients 
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in the low LGR5 group (median 55 weeks; 95% CI, 5.1 to 104.9) (p = 0.013). Although  
non-significant, there was a trend (p = 0.061) for a better OS in the group of patients with low LGR5 
(median 179 weeks; 95% CI, 74.9 to 283.1) compared with the group with increased LGR5 blood 
levels (median 61 weeks; 95% CI, 28.6 to 93.4) (Figure 3). 
Figure 3. LGR5 and survival analysis. Kaplan-Meier plots of (a) progression-free survival 
(PFS) and (b) overall survival (OS) in colorectal cancer patients according to LGR5 mRNA 
expression in blood. Relative quantification of LGR5 mRNA was calculated by the 2
−Ct
 
method using HPRT as a reference gene. Continuous mRNA levels were converted to a 
dichotomous variable using the mean levels of expression as a threshold. p estimates by log-rank 
test. Hazard ratios (HR) were modeled using Cox proportional hazard regression analysis. 
  
(a) 
 
(b) 
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High mRNA in PB (combined AGR2 and/or LGR5 transcript above the threshold cutoff) was found 
in 0, 36.4% and 53.8% of stage I–II, III and IV patients, respectively (χ2 test; p = 0.05). 
Patients were divided into favorable mRNA profile (both AGR2 and LGR5 below the mean) and 
unfavorable mRNA profile (AGR2 and/or LGR5 above the mean). At the time of analysis, the mean 
and the median PFS in the favorable group were 190.8 weeks (95% CI, 131.2 to 250.4 weeks) and not 
reached in the unfavorable group. The mean and the median PFS were 54.7 weeks (95% CI, 21.2 to 
88.1 weeks) and 32 weeks (95% CI, 17.5 to 46.6 weeks) in the unfavorable mRNA profile group  
(log-rank test p = 0.002) (Figure 4). 
Figure 4. Combined AGR2/LGR5 and survival analysis. Kaplan-Meier plots of  
(a) progression-free survival (PFS) and (b) overall survival (OS) in colorectal cancer 
patients according to combined AGR2/LGR5 mRNA profile in blood. Relative 
quantification of mRNA was calculated by the 2
−Ct
 method using HPRT as a reference 
gene. Patients were divided into favorable mRNA profile (both AGR2 and LGR5 below the 
mean) and unfavorable mRNA profile (AGR2 and/or LGR5 above the mean). p estimates 
by log-rank test. Hazard ratios (HR) were modeled using Cox proportional hazard 
regression analysis.  
 
(a) 
 
(b) 
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Multivariate Cox regression analyses were performed to determine whether high mRNA in blood 
were independently statistically predictive of PFS or OS (Table 3). 
Table 3. Progression-free survival and overall survival in relation to clinic and 
pathological characteristics and blood AGR2/LGR5 mRNA: Multivariate Cox proportional 
hazard analysis.  
  Wald Hazard Ratio 95% CI p 
Progression free survival     
Depth of invasion pT1-2/pT3/pT4 1.042 1.430 0.720 2.841 0.307 
Lymph Nodes Negative/Positive 0.834 1.714 0.539 5.445 0.361 
Residual disease R0-1/R2 8.047 5.824 1.724 19.68 0.005 
AGR2/LGR5 Negative/Positive 6.025 2.803 1.231 6.385 0.014 
Overall survival      
Depth of invasion pT1-2/pT3/pT4 0.741 1.443 0.626 3.322 0.389 
Lymph Nodes Negative/Positive 0.020 1.085 0.348 3.384 0.888 
Residual disease R0-1/R2 7.041 7.338 1.683 31.99 0.008 
AGR2/LGR5 Negative/Positive 1.158 1.594 0.682 3.724 0.282 
AGR2/LGR5 negative in blood indicate both mRNA markers below the mean; a positive result indicates 
AGR2 and/or LGR5 above the mean. 
In testing for the independent prognostic significance of high AGR2/LGR5 expression in a model 
with pT depth of invasion, lymph node involvement and residual disease (R resection status), the  
R status (HR of recurrence, 5.8; 95% CI, 1.7 to 19.7; p = 0.005) and the high mRNA blood expression 
(HR, 2.8; 95% CI, 1.2 to 6.4; p = 0.014) remained associated with PFS (Table 3). In this model, the 
only factor that retained independent prognostic significance for OS was R2-residual disease  
(HR of death, 7.338; 95% CI, 1.683 to 31.985; p = 0.008). 
2.2. Discussion 
Highly sensitive detection of CTC and detailed molecular characterization of rare cancer cell 
subpopulations may not only provide insights into the biology of early metastatic spreading, but these 
tools can also potentially indicate substantial predictive or prognostic information. PCR amplification 
of tumor mRNA is a powerful analytical tool for surrogate detection and characterization of CTC. 
Real-time RT-PCR allows for quantification of the tumor cell load in the PB and, at least theoretically, 
the determination of cutoff values of mRNA expression of clinical relevance in cancer patients. 
However, the sensitivity and specificity of this approach both depend on the expression level of 
candidate biomarkers in tumor cells as well as their background expression in the blood [26,27].  
Evidence is rapidly accumulating that cancers are composed of heterogeneous populations of cells. 
Thus, one would predict that CTC might be enriched in cancer cells that express those biomarkers 
indicating the greatest invasive and metastatic capacity, including cancer stem cells (CSC) markers. 
Hence, the selection of appropriate target mRNAs that may be useful for clinical detection of CTC and 
CSC remains an important outstanding issue. 
The current study was intended to assess the diagnostic performance of quantitative RT-PCR 
detection of AGR2 in the blood as a surrogate marker of CTC. We then hypothesized that a marker 
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indicative of the phenotype of colonic stem cells, such as LGR5, would improve the detection of 
biologically and clinically relevant CTC.  
We found that AGR2 mRNA was significantly elevated in the blood of patients with CRC compared 
to controls. ROC analysis suggested that at 94.7% specificity, AGR2 achieved 62.8% sensitivity in 
distinguishing CRC blood samples from the control group. Furthermore, in CRC patients, blood AGR2 
mRNA levels correlated with different pathological prognostic factors, including pT3–pT4 depth of 
invasion and high-grade tumors.  
These results are in line with the current evidence indicating that AGR2 can promote cancer growth, 
cell survival, migration and anchorage-independent growth and cellular transformation [14,28]. In the 
clinical setting, AGR2 protein expression in the primary tumor is an independent prognostic indicator 
of poor outcome in patients with breast [29] and prostate adenocarcinomas [30], and one recent study 
showed that increased AGR2 protein in plasma is associated with ovarian cancer [31].  
However, to the best of our knowledge, no comprehensive report has been published about the 
potential prognostic relevance of AGR2 in colorectal cancer. Our findings indicate for the first time 
that the quantitative assessment of AGR2 mRNA in blood might indicate a poor patient outcome in 
CRC. Remarkably, in stage I to III patients, the risk of disease progression was higher with increasing 
levels of AGR2 in the blood. Likewise, in CRC patients with high AGR2 blood expression, the PFS 
was significantly reduced, and there was a numerical but non-significant inferior OS. 
A recent study [32] demonstrates that AGR2 induces the expression of the growth-promoting EGFR 
ligand amphiregulin in human adenocarcinomas. This effect is mechanistically mediated through  
Yes-associated protein (YAP1) dephosphorylation. Interestingly, YAP1 is also implicated in the 
regulation of stem cell division through the repression of the Hippo pathway. These data and a 
previous report [14] show that proliferating and non-proliferating ISCs, as well as transit-amplifying 
cells from a secretory lineage express AGR2 and suggest additional mechanisms for oncogenic actions 
for AGR2.  
We next explored the expression of the ISC marker LGR5 in the blood of our cohort of controls and 
CRC patients. We found that LGR5 mRNA was significantly elevated in the blood of patients with 
colorectal carcinoma compared to controls. However, mean levels of LGR5 mRNA were similar in 
controls and early stage CRC patients. Nevertheless, there was a significant increase of LGR5 in blood 
obtained from metastatic CRC patients. When a cutoff point was defined based on the ROC curve, the 
LGR5 assay achieved only 18.8% sensitivity but 100% specificity in distinguishing CRC and control 
blood samples. Conversely, LGR5 mRNA in the blood showed a significant correlation with  
high-grade tumors, metastatic disease and R2 resections. Likewise, LGR5 expression in the blood 
showed a prognostic value regarding both PFS and OS in CRC patients, as suggested by the Cox 
regression and Kaplan-Meier analysis. In that sense, our results suggested that LGR5 is expressed only 
in a rare subset of CTC possibly including cancer stem-like cells. We could speculate that these 
circulating LGR5-expressing cells might contribute to cancer progression and therapeutic response.  
The clinical and biological significances of LGR5 expressing-cells in CRC are poorly understood.  
A primary tumor profile that encompasses known ISC markers, such as LGR5, has been strongly 
associated both with CRC stages and the occurrence of tumor relapse and metastasis [33]. LGR5 
protein expression had been associated with a poor PFS in CRC patients [22]. In contrast, in a recent 
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report [34] a gene signature defined by methylation silencing of the Wnt-driven ISC marker genes, 
including LGR5, in CRC tumors was associated with a poor prognosis.  
A number of proposed CSC markers, such as CD44 and CD133, have been explored in CTC 
detection. Recently, Iinuma H. et al. [7] demonstrated in patients with Dukes‘ stage B and C CRC that 
the detection of CEA/Cytokeratins (CK) 19/20/CD133 mRNA in blood was useful for determining 
which patients were at high risk for recurrence and poor prognosis. However, in the CD133  
single-marker analysis, no significant differences in OS and PFS were found [7]. In metastatic CRC, 
the transcriptional amount of CD133 in blood before resection of hepatic metastases resulted in a high 
risk of dying of recurrence after apparently curative liver surgery [35]. Nonetheless, CD133 and other 
putative markers for CRC stem cells such as CD44 are also expressed in a variety of cells including 
hematopoietic and/or endothelial cells (reviewed Hundt, S. in [27]), a factor that could diminish their 
specificity. The expression patterns of LRG5 and colon differentiation markers such as cytokeratin−20 
are mutually exclusive [33] are of special interest for CTC detection. These facts strengthen the 
relevance of non-CK mRNA biomarkers for the detection of the most aggressive and specific 
subpopulations of CTC in CRC patients. 
CTC in gastrointestinal cancer patients are increasingly detected when blood is obtained  
per- or intra-operatively [36]. However, the postoperative sampling time might reflect the most 
relevant CTC status [4,37]. In our study, blood samples were obtained several weeks after surgery. In 
order to explore the possible influence of recent surgery on the circulation of tumor cells, AGR2 and 
LGR5 levels were analyzed according to time intervals between surgery and blood sampling; 
conversely, no significant differences in biomarker mRNA levels between time intervals were found.  
From a clinical perspective, assessment of baseline prognostic factors and CTC detection rates may 
be of interest. In previous studies [38,39] including patients with metastatic CRC, the number of CTC 
detected using the Cell Search System was associated with high LDH level, liver metastasis and poorer 
performance status. Hence, we performed an exploratory analysis in the subset of stage IV CRC 
patients, which showed no association between a positive mRNA result and baseline clinical 
prognostic subgroups categorized according to performance status, white blood cell count, alkaline 
phosphatase and number of metastatic sites. In addition, levels of AGR2 and LGR5 were not 
significantly different either.  
The combined AGR2 and LGR5 assay resulted in an increased sensitivity (67.4%;  
AUC-ROC = 0.767; p = 0.001) to separate cancer patients and controls. Remarkably, and in spite of the 
limited number of patients, Cox multivariate analysis demonstrated that AGR2/LGR5 mRNA detection 
was a significant prognostic factor for PFS (HR, 2.8; 95% CI, 1.2 to 6.4; p = 0.014). Thus, the 
transcriptional amount of AGR2/LGR5 in the PB defined subgroups of CRC patients with significantly 
different risks of disease progression, improving the so-called biologic specificity [40] of CTC detection. 
Our findings indicate a high sensitivity and specificity for AGR2/LGR5 qRT-PCR for the surrogate 
detection of CTC in PB samples and it could be useful as a prognostic factor in patients with CRC. 
However, taking into account the design and sample size of the study, the outcome results could only 
be considered as generating a hypothesis. Additional possible limitations of this study must be 
considered. Although the inclusion of patients with different stages and residual tumor status could be 
considered limitations of the study, we suggest that this pragmatic design accurately reflects the 
patients attending the oncology clinic every day. Thus, the diagnostic performance of mRNA 
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quantification has been estimated in a cohort of patients truly representative of those found in the 
clinical setting. However, to adequately assess the prognostic role, if any, of AGR2 and LGR5 mRNA 
levels in the blood, a larger, more homogeneous cohort of patients is clearly needed. Furthermore, a 
comparative study with immunofluorescence-based methods such as the Cell Search System is warranted.  
3. Experimental Section 
3.1. Patients  
Consecutive patients with CRC from the Medical Oncology Unit at the University Hospital in La 
Coruña (Galicia, Spain) were included in the study. Inclusion criteria were as follows: A confirmed 
pathological diagnosis of colorectal adenocarcinoma; stage I–III patients with no prior systemic 
therapy for cancer; or stage IV patients without previous systemic therapy or with confirmed cancer 
progression after such treatment. Exclusion criteria were defined as follows: Any other previous 
malignancy; coagulations disorders; platelet count less than 20.0 × 10
9
 L
−1
.  
The diagnostic work-up included a clinical examination, blood sampling with CA 19.9 and CEA 
serum determination, endoscopy (when clinically indicated), thoracic radiograph and computed 
tomography (CT) scanning of the abdomen and pelvis. Chest CT was performed in patients with rectal 
tumors and stage IV patients. Patients were followed up with imaging every 8 to 12 weeks to monitor 
disease progression. 
Serum CEA (with an upper limit of normal of 5 ng/mL) and CA 19.9 (with an upper limit of normal 
of 37 U/mL) levels were determined using enzyme immunoassay (Advia Centaur, Siemens Healthcare 
Diagnostics) according to the manufacturer‘s instructions. 
PBs for qRT-PCR analyses were obtained after surgery, before neo-adjuvant chemotherapy or in 
the presence of active, clinically and radiological advanced progressive disease. At least the first 5 mL 
of blood obtained was discarded to avoid contamination with epidermal cells. 
Controls were consecutively recruited from the patients‘ family and relatives. We only excluded 
controls with a previous history of malignant disease. Thus, controls with different chronic but stable 
diseases (e.g., hypertension, diabetes mellitus or heart disease) were eligible and consecutively 
recruited. Controls were selected to include a sex and age distribution that was comparable to the 
patient group.  
This study was approved by the Ethics Committee of Clinical Investigation of Galicia (Spain), and 
written informed consents were obtained from all patients and controls prior to their inclusion in the study. 
3.2. Pathological Analysis  
Tumors and regional lymph nodes collected during surgery were processed on a routine diagnostic 
basis. Histological tumor type, depth of invasion and nodal involvement were analyzed, and the 
disease was staged and graded according to the TNM [41].  
Residual disease status at the time of blood sampling was classified as R0 when no residual disease 
was present after surgery, R1 when microscopic residual disease was found, and R2 in the presence of 
macroscopic disease. Patients from whom the blood was obtained before the start of neo-adjuvant 
treatment were categorized as R2. 
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3.3. Processing of Blood Samples and mRNA Isolation 
Peripheral venous blood (10 mL) was collected in EDTA-containing tubes. Samples were stabilized 
within 1 h after withdrawal in guanidinium-based RNA/DNA reagent (Roche, Germany) at 10% (v/v) 
without cell and plasma separation. An isolation reagent for blood and bone marrow  
(Roche, Germany) was used for mRNA extraction according to the manufacturer‘s protocol with 
minor modifications [10]. Purified poly(A) + RNA was further processed for qRT-PCR or stored at 
−80 °C until use.  
The RNA concentration was determined based on UV absorption at 260 nm. The A260/A280 ratio 
was calculated to assess RNA quality and purity.  
3.4. Reverse Transcription and Quantitative Real-Time PCR  
Reverse transcription (RT) was performed on 0.02 µg of mRNA using the Superscript First-Strand 
Synthesis System (Invitrogen Life Technologies, Carlsbad, CA, USA) as described previously [10]. 
Real-time PCR analysis was performed using the following primers: AGR2-2F, 
CTGGCCAGAGATACCACAGTC; AGR2-2R, AGTTGGTCACCCCAACCTC; LGR5-F, 
CAGCGTCTTCACCTCCTAC; LGR5-R, TTTCCCGCAAGACGTAACTC. The AGR2 and LGR5 
primers amplified 101 bp and 108 bp of the respective cDNAs. Primer pairs were chosen so that the 
sequences were located in different exons. Hypoxanthine-guanine phosphoribosyl-transferase 1 
(HPRT1) was selected as reference gene, as previously reported [8]. HPRT1 (102 bp) was also used as 
an internal control to verify the RNA integrity and the efficacy of reverse transcription. Any specimen 
with inadequate HPRT1 mRNA was excluded from the study.  
The PCR reaction consisted of 10 µL of 2× SYBR Green I Master Mix (Roche, Germany), 1.4 µL 
of forward (F) and reverse (R) primers at 5 μmol/L (Tib MolBiol, Germany), 4 µL of cDNA and  
PCR-grade water up to a final volume of 20 µL following the manufacturer‘s recommendations. 
Amplifications were performed in a Light Cycler 480 (Roche Applied Science, Penzberg, Germany).  
The maximum number of cycles was 50. If after 40 cycles no fluorescent signal was detected on the 
amplification plots, the marker mRNA was assumed to be absent from the sample. 
We verified that the amplifications and the size of each PCR product were specific by melting curve 
analysis. Data analysis was performed with Light Cycler 480 Relative Quantification software (Roche 
Applied Science, Penzberg, Germany). Relative levels of expression were calculated by the 2
−Ct
 
method [42]. Each assay was done at least in triplicate. The average value of the replicates was used as 
the quantitative value for each sample.  
Each assay included marker-positive, marker-negative and no-template controls. RNA analyses 
were performed with no knowledge about clinical or follow-up data. 
3.5. Study Design and Statistical Analysis  
This project was designed as a prospective early-phase, diagnostic case-control study. The primary 
aim was to estimate the diagnostic performances of AGR2 and LGR5 in blood as clinical  
biomarkers [43]. Receiver operating characteristic (ROC) curves were constructed by plotting 
sensitivity (y-axis) versus 1-specificity (false-positive rate; x-axis), and the area under the curve (AUC) 
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was calculated. The optimal cutoff for mRNAs expression level that separates cancer patients and 
controls was obtained at the point of the maximum Youden index. Binary logistic regression analyses 
were used to assess for diagnostic suitability of marker combinations. 
Secondary aims included the evaluation of AGR2 and LGR5 mRNA blood levels in CRC patients 
according to the disease characteristics and clinical outcomes. Parametric tests were used to analyze 
the potential correlation between mRNA biomarker expression and clinical and pathological features 
of study subjects.  
PFS was measured as the time between the baseline PB sampling for biomarkers analysis and the 
documentation of the first tumor progression based on clinical and radiological findings or death of 
any cause. OS was defined as the time from baseline blood sampling to death of any cause. Patients 
who were alive and progression-free at the time of analysis were censored by using the time between 
the baseline PB sampling and their most recent follow-up evaluation. The Kaplan-Meier method was 
used to estimate PFS and OS. Log-rank tests were used to assess the difference between the survival 
curves. Hazard ratios (HR) were modeled using Cox proportional hazard regression analysis. 
All statistical tests were two-sided, with alpha levels lower than 0.05 considered statistically 
significant. PASW Statistics 18.0 for Windows (version 18.0; IBM Corporation: Armonk, NY, USA, 
2010) was used for statistical analysis. 
The study design and results are presented in accordance with the REMARK [44] and MIQE 
guidelines [45]. 
4. Conclusions  
Our findings indicate that the quantitative molecular assessment of AGR2 and LGR5 can serve as a 
surrogate marker of CTC and ISC-like circulating tumor cells in CRC patients. Elevated AGR2 and 
LGR5 mRNA levels in the blood are associated with poor outcome in patients with CRC.  
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